PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.\', \'Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.\', \'CureVac AG, Tübingen, Germany.\', \'Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.\', \'Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.\', \'Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. anca.dorhoi@fli.de.\', \'Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. martin.beer@fli.de.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41467-021-24339-7
?:doi
?:hasPublicationType
?:journal
  • Nature communications
is ?:pmid of
?:pmid
?:pmid
  • 34193869
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.582
?:rankingScore_hIndex
  • 198
?:title
  • CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34193869>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34193869>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all